Stockreport

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

Acorda Therapeutics, Inc.  (ACOR) 
Last acorda therapeutics, inc. earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: acorda.com/investors
PDF PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced it will regain global commercialization rights to FAMPYRA® (fampridine) [Read more]